COVID-19 medicine share in pharma revenue in Russia 2021, by company

Published by Statista Research Department, May 4, 2023
Over 91 percent of the total revenue of the Russian pharmaceutical company R-Pharm came from sales of medicines for treatment of the coronavirus (COVID-19) in 2021. Furthermore, COVID-19 drug sales accounted for almost 46 percent of the revenue of Pfizer in Russia.

Share of medicines for COVID-19 treatment in the total revenue in Russia in 2021, by pharmaceutical company

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

February 2022

Region

Russia

Survey time period

2021

Supplementary notes

Companies with the largest share of COVID-19 medicines in their revenue are presented.

Citation formats
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$69 USD $49 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you

Overview

8

Segments

7

Companies and brands

7

Pharmacies

5

Online retail

4

Trade

7

Further Content: You might find this interesting as well

Topics

Coronavirus (COVID-19) in RussiaCOVID-19 impact on the gaming industry worldwidePfizerBioNTechModerna
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Learn more about how Statista can support your business.
Menu